Clinical Trial Update: Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

View source ↗

Summary

This clinical trial update discusses Melanoma Inhibitory Activity (MIA) as a serological marker for metastatic uveal melanoma. The sponsor is Ludwig-Maximilians…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Uveal Melanoma

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Melanoma, Radiotherapy | Status: UNKNOWN